A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
108actual
Sites
3
Countries
Germany, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-01 | actual | When the study began enrolling |
| Primary completion | 2026-01-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-13 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Biological: AZD1163
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured From Day -1 until end of study (Day 450)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed